Related by context. All words. (Click for frequent words.) 80 Antitumor Activity 80 Investigational Compound 79 Prolongs Survival 79 Phase 2b Clinical Trial 79 Drug Candidate 79 Anti Tumor 79 Demonstrated Significant 79 Protease Inhibitor 79 Meets Primary Endpoint 78 Phase IIb Trial 78 Clinical Trial Results 78 Study Evaluating 78 Shows Promising 78 Lupus Drug 77 Epilepsy Drug 77 Improves Survival 77 Phase 2a Clinical Trial 77 Phase 2b Trial 77 Drug Shows Promise 77 Phase III Trials 77 Oral Fingolimod 76 Kinase Inhibitor 76 Advanced Melanoma 76 Improves Outcomes 76 Present Preclinical Data 76 Treated Patients 76 Novel Antibiotic 76 Investigational Drug 76 Initiate Phase 76 Single Dose 76 Dose Escalation 76 Survival Benefit 76 See CLINICAL PHARMACOLOGY 76 Phase IIb Clinical Trial 76 Previously Treated 76 Drug Combo 76 Combination Treatment 76 Patients Receiving 75 Peginterferon 75 Monoclonal Antibody 75 Demonstrates Significant 75 Data Suggest 75 Preclinical Data 75 Gout Drug 75 Cholesterol Lowering Drug 75 Advanced Prostate Cancer 75 Vaccine Adjuvant 75 Submits NDA 75 Infected Patients 75 Is Well Tolerated 75 Demonstrates Positive 75 Blood Pressure Drug 75 Phase 2b Study 75 Completes Patient Enrollment 75 Lung Cancer Drug 75 Shows Efficacy 75 Phase III Clinical Trial 75 Metastatic Melanoma 75 Osteoporosis Drug 75 Pooled Analysis 75 Pharmacokinetic Study 75 Chronic Hepatitis C 75 Improved Survival 75 Antiviral Activity 75 Lung Cancer Trial 75 Disease Progression 75 Presents Preclinical Data 75 Rotavirus Vaccine 75 Study Showed 75 Relapsing Multiple Sclerosis 75 Fungal Infections 75 Prostate Cancer Vaccine 75 Long Term Efficacy 75 Statistically Significant 75 Newly Diagnosed Multiple Myeloma 75 Investigational Agent 74 Pivotal Phase 74 Peginterferon Alfa 2a 74 Prostate Cancer Patients 74 Well Tolerated 74 Adjunctive Therapy 74 IND Application 74 Investigational Treatment 74 Significantly Improved 74 Improve Survival 74 Disease Modifying 74 Phase 2a Trial 74 Interferon Beta 74 Adjuvant Treatment 74 Inflammatory Markers 74 Low Dose 74 Trial Evaluating 74 Patient Enrollment 74 Treatment Naive Patients 74 Osteoporosis Treatment 74 Rheumatoid Arthritis Patients 74 Anticancer Activity 74 Initiates Clinical 74 Patients Treated With 74 Anti Tumor Activity 74 Appears Safe 74 Pivotal Study 74 HCV Protease Inhibitor 74 Proves Effective 74 Renal Cell Carcinoma 74 Phase IIa Clinical Trial 74 Novel Mechanism 74 Mg Usa 74 Drug Fails 74 Breast Cancer Recurrence 74 Transdermal Patch 74 Insulin Glargine 74 Monotherapy 73 FDA Approvals 73 Phase III Trial 73 Hepatitis C Genotype 73 JAK Inhibitor 73 Advanced Pancreatic Cancer 73 Shown Effective 73 Plus Ribavirin 73 Vaccine Candidate 73 FDA Accepts 73 Hormone Refractory Prostate Cancer 73 FDA Okays 73 Treatment Naïve 73 Antitumor 73 Antidepressant Drug 73 Novel Oral 73 Hypertensive Patients 73 Adjuvant Chemotherapy 73 Complicated Skin 73 Arthritis Drug 73 Initiates Clinical Trial 73 Treating Chronic 73 Oral Calcitonin 73 Successfully Completes Phase 73 Metastatic Prostate Cancer 73 Mylan Receives Approval 73 Tyrosine Kinase Inhibitor 73 Kidney Transplant Patients 73 Completes Enrollment 73 Immune Responses 73 Combination REOLYSIN R 73 Pegylated Interferon 73 Viral Suppression 73 Presents Positive 73 Showed Significant 73 Treatment Reduces 73 Versus Placebo 73 Cholesterol Drug 73 Antiangiogenic 73 Severe Sepsis 73 Rheumatoid Arthritis Drug 73 Statin Therapy 73 Clinical Trial Data 73 Randomized Double Blind 73 Patients Treated 73 Receives Orphan Drug Designation 73 Synthetic Peptide 73 Potent Antiviral Activity 73 Treatment Experienced 73 Pivotal Phase III 73 Fixed Dose 73 Phase 1b Clinical Trial 72 Demonstrates Efficacy 72 Patients Suffering 72 Advanced Colorectal Cancer 72 Phase III Clinical Trials 72 PRN FDA Approves 72 Shows Promise Against 72 Tumor Growth 72 Combo Therapy 72 Treatment Regimen 72 Hematological Cancers 72 Generic Version 72 Anticancer Drug 72 Psoriasis Drug 72 Experimental Vaccine 72 Achieves Primary Endpoint 72 Antifungal 72 Parathyroid Hormone 72 Fast Track Status 72 Seasonal Influenza Vaccine 72 Slow Progression 72 Treatment Shows Promise 72 Multiple Myeloma Patients 72 Vaccine Protects Against 72 Teva Provides Update 72 Tiotropium 72 Gene Variant 72 Hormone Receptor Positive 72 Pediatric Patients 72 Double Blind Randomized 72 Lung Cancer Survival 72 Therapeutic Efficacy 72 Tolerability 72 FDA Clears 72 Relapsed Refractory 72 Erectile Dysfunction Drug 72 Aurora Kinase 72 HDAC Inhibitor 72 HER2 Positive 72 Drug Resistant 72 Unfractionated Heparin 72 Therapeutic Antibody 72 RNAi Therapeutic 72 Prostate Tumors 72 Migraine Drug 72 NDA Submission 72 Initiate Clinical Trial 72 Study Demonstrates 72 Universal Flu Vaccine 72 Breast Tumors 72 Hsp# Inhibitor 72 Sustained Reduction 72 Viral Load 72 Naive Patients 72 Nicotine Vaccine 72 Oral Cladribine 72 Receives Approvable Letter 72 Vicriviroc 72 Oral Formulation 72 Preclinical Study 72 Controlled Trial 72 Inhaled Corticosteroids 72 Effectively Treats 72 Demonstrates Statistically Significant 72 Shingles Vaccine 72 Randomized Phase 72 Anemia Drug 72 Refractory Hodgkin Lymphoma 72 Lowers Risk 72 Vitro Activity 72 Aliskiren 72 Confirmatory Phase 72 Vildagliptin 71 Tezampanel 71 JAK2 Inhibitor 71 Placebo Controlled Trial 71 Initiates Enrollment 71 Demonstrates Potential 71 Chemotherapy Improves 71 Premenopausal Women 71 Hemodialysis Patients 71 Novel Inhibitor 71 Myeloma Patients 71 Schizophrenia Drug 71 Drug Prevents 71 Pulmonary Arterial Hypertension 71 Generic Versions 71 Fewer Side Effects 71 Proven Effective 71 Bone Metastases 71 Bosutinib 71 First Patient Enrolled 71 Combination Therapy 71 First Patient Dosed 71 Inhaled Nitric Oxide 71 Skin Lesions 71 Gene Linked 71 Protease Inhibitors 71 Clinical Trial Evaluating 71 Polymerase Inhibitor 71 Intravenous Formulation 71 Significantly Improves 71 Anti Inflammatory 71 Anthracycline 71 II Clinical Trial 71 Initiates Phase II 71 Novel Anticancer 71 Files IND 71 Extended Release 71 Initiates Phase III 71 Resistant Hypertension 71 IND Filing 71 Prove Effective 71 Anti Clotting Drug 71 Pafuramidine 71 Preclinical Models 71 Therapeutic Potential 71 Sapacitabine 71 Study Shows Promise 71 Randomized Clinical Trials 71 Mouse Model 71 Milestone Payment 71 Cholesterol Lowering 71 Anti Inflammatory Drug 71 Artery Disease 71 Calcium Vitamin D 71 Fracture Risk 71 Inhaled Insulin 71 Orally Active 71 Previously Untreated 71 Placebo Controlled Study 71 Protein Linked 71 Hepatitis C Patients 71 Double Blind Placebo 71 Immunotherapeutic 71 Recombinant Human 71 Valopicitabine 71 Collaborators Present 71 Pharmacyclics Announces 71 Regimens 71 Breast Cancer Cells 71 Cholesterol Drugs 71 Diabetic Nephropathy 71 Tigecycline 71 Kidney Function 71 Commonly Prescribed 71 Knee Osteoarthritis 71 Randomized Phase II 71 Significantly Reduced 71 Randomized Double blind 71 Earns Milestone Payment 71 Osteoporosis Drugs 71 Elderly Patients 71 Nymox NX 71 Lung Cancer Patients 71 Inhibits 71 Weight Loss Drug 71 Newly Diagnosed 71 Cethromycin 71 Anticoagulant 71 Neoadjuvant Chemotherapy 70 Metastatic Colorectal Cancer 70 Aflibercept 70 Immunomodulatory 70 Lupus Nephritis 70 Reports Preclinical Data 70 Immunogenicity 70 Schizophrenia Treatment 70 Chronic Hepatitis B 70 Adjuvant Therapy 70 Antiviral Drugs 70 FDA Approves Drug 70 Dose Response 70 Novel Therapeutic 70 HER2 Positive Breast Cancer 70 Receptor Antagonist 70 Maribavir 70 Smooth Muscle 70 Chemoradiation 70 Telaprevir VX 70 Chemotherapy Regimen 70 Adefovir 70 Unresectable 70 Study Shows Benefits 70 Therapy Improves 70 Pivotal Trials 70 Antiplatelet 70 Epilepsy Drugs 70 Cocaine Addiction 70 Critically Ill Patients 70 Nebulized 70 Menopausal Women 70 TO AVOID PREGNANCY WHILE 70 Acute Migraine 70 Initiate Phase III 70 CYP#A# CYP#D# 70 Atypical Antipsychotics 70 Combination Vaccine 70 Phase III Pivotal Trial 70 Aggressive Prostate Cancer 70 Medoxomil 70 Diabetic Neuropathy 70 Partial Onset Seizures 70 Randomized Clinical Trial 70 Potent Anti 70 Pharmacokinetics PK 70 Tipranavir 70 Advanced Ovarian Cancer 70 Autologous Stem Cell Transplantation 70 Tumor Response 70 Beneficial Effects 70 Demonstrate Significant 70 Meta Analysis 70 FDA APPROVES 70 Blood Thinner 70 Colorectal Cancer Patients 70 Cutaneous T 70 Testosterone Patch 70 Initiates Phase 70 Hypercholesterolemia 70 Postmenopausal Osteoporosis 70 Efficacious 70 Patient Enrolment 70 MEK Inhibitor 70 Potentially Fatal 70 ADHD Medication 70 Malaria Vaccine 70 Relapsing Remitting Multiple Sclerosis 70 Glucose Control 70 AnaSpec Introduces 70 Reduces Risk 70 Phase Ib Clinical Trial 70 Interferon Gamma 70 Sustained Efficacy 70 Inflammatory Disease 70 Plaque Psoriasis 70 Demonstrates Sustained 70 Test Detects 70 Receptor Agonist 70 Controlled Study 70 Subgroup Analysis 70 Inflammatory Arthritis 70 Smallpox Vaccine 70 Hepatitis C Infection 70 Immunomedics Announces 70 Diabetic Patients 70 Castration Resistant Prostate Cancer 70 Asthma Treatment 70 Soft Tissue Sarcoma 70 Capecitabine 70 Secondary Hyperparathyroidism 70 Relapsed Multiple Myeloma 70 Obesity Linked 70 Premature Infants 70 Nuvelo Announces 70 Flamel Technologies Announces 70 Mimetics 70 Myelodysplastic Syndromes 70 Epidermal Growth Factor Receptor 70 Liver Toxicity 70 Capsules CII 70 Ovarian Cancer Patients 70 Hormone Therapy 70 Estrogen Therapy 70 Initiates Phase 2b 70 Chronic Myeloid Leukemia 70 Commonly Used 70 Systemic Delivery 70 Commence Phase 70 Treat Anemia 70 Immune Cells 70 Commences Phase 70 Renal Impairment 70 Moderate Drinking 70 Patients Enrolled 69 Malignant Glioma 69 Factor Receptor 69 Hepatitis C Virus 69 Treatment Naive 69 Gastric Cancer 69 Epoetin Alfa 69 Antipsychotic Drug 69 Visceral Fat 69 Anticancer Compound 69 Cardiotoxicity 69 Romidepsin 69 Acute Pancreatitis 69 Develop Novel 69 Postmenopausal Women 69 Genes Linked 69 Immunosuppressant 69 Presents Preclinical 69 Pre Cancerous 69 Files Investigational 69 Statin Drugs 69 Levels Linked 69 Generic Version Of 69 Increased Mortality 69 Small Molecule 69 Therapeutic Vaccine 69 FDA Panel Recommends 69 Attenuates 69 Multicenter Trial 69 Hepatitis B Vaccine 69 Non Responders 69 Advanced Renal Cell 69 Clinical Outcome 69 Decitabine 69 Chemotherapeutic Agents 69 Predict Risk 69 Human Monoclonal Antibody 69 Bare Metal Stents 69 ritonavir boosted 69 Poniard Pharmaceuticals Announces 69 Platelet Inhibition 69 Anticancer Agent 69 Malignant Melanoma 69 Cardiovascular Events 69 Boosts Survival 69 Heartburn Drugs 69 Expanded Indication 69 Leukemia Cells 69 Therapy Reduces 69 Granted Orphan Drug 69 Blood Pressure Drugs 69 Oral Mucositis 69 Reduces Pain 69 Heart Failure Patients 69 Milestone Payments 69 SPRYCEL ® 69 Desvenlafaxine Succinate 69 Antibiotic Use 69 Glatiramer Acetate 69 Hormonal Therapy 69 Lowers Blood Pressure 69 STELARA TM 69 Medullary Thyroid Cancer 69 Beta Blocker 69 HCV Genotype 69 Humanized Anti 69 Oral Insulin 69 Contrast Agents 69 Novel Compound 69 Septic Shock 69 Investigational Oral 69 Vaginal Gel 69 oral prodrug 69 Sangamo BioSciences Announces 69 Melphalan 69 Transplant Patients 69 Clinical Study Shows 69 Stomach Cancer 69 Genes Involved 69 Cholesterol Levels 69 Cyclophosphamide 69 Gene Mutation 69 Randomized Study 69 sunitinib Sutent ® 69 Treatment Resistant 69 Antidepressants Linked 69 Obese Patients 69 Increases Risk 69 Bone Mineral Density 69 Mg Uk 69 Osteoarthritis Patients 69 Pazopanib 69 PDUFA Date 69 Soy Isoflavones 69 Virus Linked 69 Kidney Transplant Recipients 69 non nucleoside inhibitor 69 Combination Clinical Trial 69 Clostridium difficile Infection 69 Migraine Treatment 69 Sirolimus Eluting Stent 69 Tablet Formulation 69 Diabetic Foot Ulcer 69 Breast Cancers 69 Anti Angiogenic 69 Hepatitis C Treatment 69 R lenalidomide 69 Liver Damage 69 Pegylated 69 Patients Undergoing 69 Gene Mutations 69 Allergic Rhinitis 69 Benign Prostatic Hyperplasia 69 TB Vaccine 69 Pregnancy Linked 69 Male Contraceptive 69 Topline Results 69 Nitazoxanide 69 Tuberculosis Vaccine 69 Paraplatin ® 69 pralatrexate injection folate analogue 69 Initiates Clinical Trials 69 Neutralizing Antibodies 69 Non Inferiority 69 Carboplatin Paclitaxel 69 Long Term Survival 69 FDA Warns Against 69 Radiation Induced 69 Antipsychotic Drugs 69 Antidiabetic 69 Bipolar Depression 69 Indacaterol 69 Genetic Tests 69 Receives Fast Track 69 Topical Treatment 69 Receives Orphan Drug 69 Blood Clot Risk 69 Genetic Mutation 69 Androgen Deprivation Therapy 68 Randomized Trials 68 Elevated Levels 68 Aspirin Reduces 68 Renal Cancer 68 alfa 2a 68 Peginterferon Alfa 2b 68 Calcium Supplements 68 Reduced Risk 68 Prophylactic Treatment 68 BioSante Pharmaceuticals Reports 68 Treatment Naive HIV 68 Receptor Antagonists 68 Novel Treatments 68 Hematological Malignancies 68 Hepatocellular Carcinoma 68 Breast Cancer Treatment 68 Nanoemulsion 68 Clinical Evaluation 68 Symptom Relief 68 Stem Cell Transplants 68 Prospective Randomized 68 Allogeneic 68 Posaconazole 68 Azacitidine 68 Autoimmune Diseases 68 Node Positive 68 adalimumab Humira 68 Dose Ranging Study 68 Cell Lymphoma 68 ACE Inhibitors 68 Predict Prostate Cancer 68 Dose Finding 68 NICE Recommends 68 Colorectal Adenomas 68 Zoledronic Acid 68 CYP#A# substrate 68 Avian Flu Vaccine 68 Study Casts Doubt 68 Anemia Drugs 68 Enoxaparin 68 Million Milestone Payment 68 Integrase Inhibitor 68 Slows Progression 68 AVI BioPharma Announces 68 Effective Than 68 Dasatinib 68 Respiratory Virus 68 Vaccine Prevents 68 Safinamide 68 Submits Biologics License Application 68 Cardiovascular Outcomes 68 Sandostatin R 68 Completes Dosing 68 Autoimmune Disease 68 Recurrent Breast Cancer 68 Immunogenic 68 Lung Cancers 68 Fondaparinux 68 Lower Blood Pressure 68 Cancer Treatments 68 Crit Rev 68 Asthma Symptoms 68 Cinacalcet 68 Endometrial Cancer 68 Submits Supplemental 68 Signaling Pathway 68 Anticancer Drugs 68 Corticosteroid 68 Extended Release Formulation 68 Diabetic Kidney Disease 68 Vaccine Shows Promise 68 Novel Therapies 68 Inhalation Solution 68 Oral Laquinimod 68 ALN HPN 68 Shows Promise 68 Randomized Controlled Trials 68 Inhaled Liposomal Ciprofloxacin 68 Prognostic Value 68 Carotid Stenting 68 Bone Marrow Cells 68 Eluting Stent 68 Serious Infections 68 Dose Ranging 68 Overactive Bladder 68 Cervical Cancer Vaccine 68 Recommends Approval 68 Renal Function 68 Genes Predict 68 Efficacy Trial 68 RNAi Therapeutics 68 AAG geldanamycin analog 68 Brain Metastases 68 Gene Variants 68 Skeletal Muscle 68 Fluticasone 68 TNF Blockers 68 Prostate Cancer Progression 68 Colorectal Cancer Risk 68 Receive Milestone Payment 68 Liver Injury 68 Study Reinforces 68 Lung Cancer Risk 68 Tumor Necrosis Factor 68 Gene Variation 68 Drug Coated Stent 68 Systemic Sclerosis 68 Preterm Delivery 68 Kidney Transplants 68 Hepatotoxicity 68 Receives Milestone Payment 68 Phospholipase A2 68 Low Doses 68 Viral Infections 68 Antigen Specific 68 Randomized Double Blind Placebo 68 Interferon Alpha 68 Significant Reduction 68 Gastric Ulcers 68 Immunologic 68 Fibromyalgia Pain 68 Adjuvanted 68 Cognitive Function 68 Oritavancin 68 Newly Diagnosed Patients 68 Hydrochlorothiazide Tablets 68 Pneumonia Vaccine 68 Ebola Vaccine 68 Novel Vaccine 68 Ranolazine 68 Clinical Efficacy 68 Immunosuppression 68 Enlarged Prostate 68 Synta Announces 68 ara C 68 Drug Maker 68 Atypical Antipsychotic 67 Transdermal Delivery 67 Influenza Vaccine 67 Cardiovascular Disease Risk 67 Endothelial Cells 67 Helps Smokers Quit 67 Cancer Stem Cells 67 Treatment Naïve Patients 67 Hepatitis B Virus 67 Tumor Cell 67 Antibody Drug Conjugate 67 Significant Improvements 67 Novel Method 67 Hepatic Encephalopathy 67 Predict Response 67 Multicenter Phase 67 Colorectal Cancers 67 Cell Transplants 67 Boceprevir 67 Preclinical Efficacy 67 Chronic Sinusitis 67 Left Ventricular Hypertrophy 67 Liver Tumors 67 Golimumab 67 relapsed MM 67 Breast Cancer Stem Cells 67 Neulasta ® 67 Glufosfamide 67 Genotypes 67 Pneumococcal Vaccine 67 Bortezomib 67 Aeolus Pharmaceuticals Announces 67 Potent Inhibitor 67 Metastatic Renal Cell Carcinoma 67 Significantly Reduces 67 Emerging Therapies 67 Cervical Dysplasia 67 Prevent Breast Cancer 67 Risedronate 67 Venous Thromboembolism 67 Second Pivotal Phase 67 Neoadjuvant 67 Fulvestrant 67 Drug Resistant Bacteria 67 Beta Blockers 67 Pandemic Flu Vaccine 67 Begins Dosing 67 Acute Attacks 67 Irinotecan 67 Pivotal Trial 67 Phase III Pivotal 67 Acne Drug 67 Ozarelix 67 Cancer Cells 67 Ovarian Cancer Risk 67 atazanavir sulfate 67 Left Ventricular Dysfunction 67 Blood Pressure Lowering 67 Localized Prostate Cancer 67 Genital Herpes 67 Pivotal Clinical Trial 67 Anti Nausea 67 Breast Tumor 67 Maleate 67 Prostate Cancers 67 Bipolar Mania 67 Confirms Efficacy 67 Radiation Dose 67 Brentuximab Vedotin SGN 67 Launches Generic Version 67 Patent Covering 67 Bavituximab 67 Randomized Controlled 67 Cancer Recurrence 67 Improve Outcomes 67 Late Breaker 67 Higher Doses 67 Cholesterol Lowering Drugs 67 Nucleoside 67 Spectrum Pharmaceuticals Announces 67 COPEGUS R 67 Guidelines Issued 67 Oral Anticoagulant 67 Sustained Release 67 Pioglitazone 67 Antibiotic Treatment 67 Omacetaxine 67 Insulin Resistance 67 Camptosar ® 67 Acute Ischemic Stroke 67 selective modulator 67 BiTE Antibody 67 Invasive Fungal Infections 67 Inhaled Steroids 67 Zovirax acyclovir 67 Montelukast 67 EGFR HER2 67 Dendritic Cells 67 PPD Declares 67 Seasonal Flu Vaccine 67 J Allergy Clin 67 Atopic Dermatitis 67 Bisphosphonate 67 Treat Heart Failure 67 CDC Recommends 67 Pramlintide 67 Mycophenolate Mofetil 67 Blood Thinning 67 Cyclooxygenase 2 67 Bacterial Infection 67 Could Prevent 67 imatinib Gleevec ® 67 Adenoviral 67 Receives Positive Opinion 67 Initiated Phase 67 Oral Cavity 67 Remission Maintenance 67 Effective Treatments 67 #mg #mg #mg [003] 67 Significant Efficacy 67 Uric Acid 67 Thrombotic 67 Gastrointestinal Stromal Tumors 67 Therapy Shows Promise 67 Bronchodilator 67 Hospital Acquired Pneumonia 67 Pharmacodynamics 67 Menopause Symptoms 67 Paclitaxel Carboplatin 67 Efficacy Results 67 Adverse Effects 67 Circulating Tumor Cells 67 Tumor Suppressor 67 Anti CD# Antibody 67 dasatinib Sprycel ® 67 Pemetrexed 67 Toremifene 67 Pharmacokinetic Profile 67 Modulates 67 Endovascular Treatment 67 Strongly Linked 67 Menopausal Symptoms 67 Technological Advances 67 Novel Peptide 67 Muscle Function 67 Gene Therapy Trial 67 Daptomycin 67 Stent Restenosis 67 Zorbtive TM 67 IIa Clinical Trial 67 Significant Improvement 67 evaluating tivozanib 67 Respiratory Syncytial Virus 67 Epratuzumab 67 Induces 67 Neuroprotective Effects 67 ANDA Filing 67 Hedgehog Pathway 67 Univest Corporation Declares 67 Therapeutic Vaccines 67 Interferon beta 1a 67 Novel Small Molecule 67 Genes Associated 67 Fluconazole 67 Bazedoxifene 67 Telbivudine 67 Brain Scans 67 Long Term Outcomes 67 Diabetic Neuropathic Pain 67 Low Density Lipoprotein Cholesterol 67 Prevent Prostate Cancer 67 Preterm Labor 67 PDL BioPharma Announces 67 Pandemic Influenza Vaccine 67 Viral Infection 67 Preterm Infants 67 Stent Thrombosis 67 Bevacizumab 67 Dengue Virus 66 Virus Infection 66 Tumor Cells 66 Excessive Sweating 66 Coadministration 66 Blood Pressure Reduction 66 Blinatumomab 66 Lipid Levels 66 Kinase Inhibitors 66 Cellular Immunotherapy 66 Lubiprostone 66 MKC# MT 66 Renal Anemia 66 FDA Approves 66 Limb Ischemia 66 Lanthanum Carbonate 66 Inflammatory Diseases 66 Morbidity Mortality 66 Cancer Vaccines 66 Tesamorelin 66 Holds Promise 66 Poorly Controlled 66 Bird Flu Vaccine 66 Biologic Therapy 66 Liver Failure 66 Novel Compounds 66 Cognitive Impairment 66 Chronic Lymphocytic Leukemia 66 Moxifloxacin 66 Immune Cell 66 Levaquin levofloxacin 66 Urine Test 66 Chemotherapeutic 66 Antipsychotic 66 Safety Tolerability 66 Doripenem 66 Breast Cancer Patients 66 Gastrointestinal Disorders 66 Ecallantide 66 Lymphoma Patients 66 IN PATIENTS WITH 66 Dose Escalation Study 66 pan histone deacetylase 66 Taxane 66 Weight Loss Pill 66 Lamotrigine 66 Vasomotor Symptoms 66 Projected Release Date 66 Am J Clin 66 Proteasome 66 Renal Cell Cancer 66 Begin Clinical Trials 66 Protein Involved 66 Progenitor Cells 66 Metabolic Efficiency 66 Detect Cancer 66 Hormone Levels 66 Sleep Disturbances 66 2 methoxyestradiol 66 novel VDA molecule 66 Osteoarthritis Pain 66 Preclinical Evaluation 66 5 Fluorouracil 66 Sevelamer 66 Brain Atrophy 66 Ovarian Cancers 66 Insulin Sensitivity 66 Follicular Lymphoma 66 Shows Statistically Significant 66 Genes Identified 66 Cognitive Decline 66 Non Invasive Treatment 66 Radical Prostatectomy 66 Successfully Treated 66 Companion Diagnostic 66 Reductase 66 Vitamin D Linked 66 Lung Tumors 66 Thyroid Hormone 66 Fabry Disease 66 Invasive Breast Cancer 66 Fluorouracil 66 Sagent Pharmaceuticals Announces 66 Aptivus ® 66 non peptidic protease 66 Systematic Review 66 BARACLUDE R 66 R Bortezomib 66 Million Doses 66 Announcement acc 66 Urinary Tract Infections 66 Entry Inhibitor 66 Clot Busting 66 #mg/#mg 66 Telik Announces 66 Tumor Targeting 66 Prodrug 66 Diet Pill 66 Less Invasive 66 Antidepressant Use 66 Nilotinib 66 Demonstrates Ability 66 Metabolic Disorder 66 Generic Protonix 66 Anti Angiogenesis 66 Histone Deacetylase 66 Radiofrequency Ablation 66 Blood Vessels 66 Postherpetic Neuralgia